<DOC>
	<DOCNO>NCT01517555</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate drug-drug interaction liraglutide paracetamol ( BenuronÂ® ) investigate effect liraglutide post prandial glucose .</brief_summary>
	<brief_title>Effect Liraglutide Absorption Paracetamol Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Type 2 diabetes mellitus Diettreated subject type 2 diabetes HbA1c 7.59.5 % Subjects type 2 diabetes oral antidiabetic drug ( OAD ) monotherapy treat metformin alphaglucosidase inhibitor HbA1c 7.09.5 % Body mass index ( BMI ) 18.540 kg/m^2 Subjects stable body weight least 3 month prior screen ( judged Investigator ) Impaired liver function Impaired renal function Clinically significant active cardiovascular disease include history myocardial infarction within last 6 month and/or heart failure Any clinically significant abnormal ECG ( electrocardiogram ) Uncontrolled treated/untreated hypertension Recurrent severe hypoglycaemia judged Investigator Active hepatitis B and/or active hepatitis C Positive human immunodeficiency virus ( HIV ) antibodies Known suspect allergy trial product ( ) relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>